Welcome to our dedicated page for Cryo-Cell Intl SEC filings (Ticker: CCEL), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Cryo-Cell International, Inc. (CCEL) SEC filings page on Stock Titan provides direct access to the company’s regulatory disclosures, along with AI-generated summaries to help interpret complex documents. As a NYSE American–listed company engaged in cellular processing, cryogenic storage, and cord blood banking, Cryo-Cell uses its SEC filings to report on financial performance, governance, financing arrangements, and material events.
Investors can review annual reports on Form 10-K for a comprehensive discussion of the company’s business, including its private and public cord blood banking operations, the role of PrepaCyte-CB processing technology, the ExtraVault biostorage offering, and the license agreement with Duke University. Quarterly reports on Form 10-Q provide interim financial data, segment revenue details such as processing and storage fees, public banking revenue, and product revenue, as well as updates on research and development spending and other operating items.
Current reports on Form 8-K document specific material events. Recent examples include disclosures about decisions to declare or not declare quarterly cash dividends, amendments to the company’s Credit Agreement with Susser Bank, and the setting of the annual meeting date and record date. These filings also describe changes to revolving credit commitments, maturity dates, and the addition of subsidiaries such as Celle Corp. as guarantors, which are relevant for understanding Cryo-Cell’s capital structure and liquidity.
The definitive proxy statement on Schedule DEF 14A outlines board composition, proposals for director elections, auditor ratification, and advisory votes on executive compensation, as well as stockholder voting procedures. Form 4 and related insider transaction reports, when available, can be used to track trading activity by directors and officers.
Stock Titan’s AI tools summarize key points from 10-K, 10-Q, 8-K, DEF 14A, and other filings, helping users quickly identify disclosures on dividends, credit facilities, governance matters, and strategic initiatives without reading every page of the original documents.
PORTNOY DAVID reported open-market purchase transactions in a Form 4 filing for CCEL. The filing lists transactions totaling 5,826 shares at a weighted average price of $4.17 per share. Following the reported transactions, holdings were 122,838 shares.